A phase II trial of MRX 34 in patients with renal cell carcinoma

Trial Profile

A phase II trial of MRX 34 in patients with renal cell carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs MRX 34 (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Mirna Therapeutics
  • Most Recent Events

    • 01 Apr 2016 New trial record
    • 29 Mar 2016 According to a Mirna Therapeutics media release, this trial is expected to initiate by the end of 2016.
    • 29 Mar 2016 According to a Mirna Therapeutics media release, the company plans to provide a clinical update from these studies in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top